356 related articles for article (PubMed ID: 37409429)
1. Genetically Engineered-Cell-Membrane Nanovesicles for Cancer Immunotherapy.
Cheng Q; Kang Y; Yao B; Dong J; Zhu Y; He Y; Ji X
Adv Sci (Weinh); 2023 Sep; 10(26):e2302131. PubMed ID: 37409429
[TBL] [Abstract][Full Text] [Related]
2. Genetically engineered cell-derived nanovesicles for cancer immunotherapy.
He S; Zhao Z
Nanoscale; 2024 May; 16(17):8317-8334. PubMed ID: 38592744
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in the Development of Membrane-derived Vesicles for Cancer Immunotherapy.
Xiao Y; Wu M; Xue C; Wang Y
Curr Drug Deliv; 2024; 21(3):403-420. PubMed ID: 37143265
[TBL] [Abstract][Full Text] [Related]
4. Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics.
Ren E; Liu C; Lv P; Wang J; Liu G
Adv Sci (Weinh); 2021 Nov; 8(21):e2100460. PubMed ID: 34494387
[TBL] [Abstract][Full Text] [Related]
5. Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy.
Lv P; Liu X; Chen X; Liu C; Zhang Y; Chu C; Wang J; Wang X; Chen X; Liu G
Nano Lett; 2019 May; 19(5):2993-3001. PubMed ID: 30964695
[TBL] [Abstract][Full Text] [Related]
6. Genetically Engineered Plasma Membrane Nanovesicles for Cancer-Targeted Nanotheranostics.
Zhang P; Chen H; Liu J; Liu G
Methods Mol Biol; 2019; 2054():283-294. PubMed ID: 31482462
[TBL] [Abstract][Full Text] [Related]
7. Application of lipid nanovesicle drug delivery system in cancer immunotherapy.
Ding Y; Wang L; Li H; Miao F; Zhang Z; Hu C; Yu W; Tang Q; Shao G
J Nanobiotechnology; 2022 May; 20(1):214. PubMed ID: 35524277
[TBL] [Abstract][Full Text] [Related]
8. Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy.
Xu C; Ju D; Zhang X
Front Immunol; 2022; 13():923598. PubMed ID: 35874757
[TBL] [Abstract][Full Text] [Related]
9. Cellular Membrane Components-Mediated Cancer Immunotherapeutic Platforms.
Yun S; Kim S; Kim K
Macromol Biosci; 2023 Nov; 23(11):e2300159. PubMed ID: 37319369
[TBL] [Abstract][Full Text] [Related]
10. Current advances in bacteria-based cancer immunotherapy.
Guo C; Liu J; Zhang Y
Eur J Immunol; 2024 Feb; 54(2):e2350778. PubMed ID: 38105295
[TBL] [Abstract][Full Text] [Related]
11. Membrane engineering of cell membrane biomimetic nanoparticles for nanoscale therapeutics.
Zhang M; Cheng S; Jin Y; Zhang N; Wang Y
Clin Transl Med; 2021 Feb; 11(2):e292. PubMed ID: 33635002
[TBL] [Abstract][Full Text] [Related]
12. Cellular Bioparticulates with Therapeutics for Cancer Immunotherapy.
Wang C; Wen D; Gu Z
Bioconjug Chem; 2018 Mar; 29(3):702-708. PubMed ID: 29227626
[TBL] [Abstract][Full Text] [Related]
13. Genetically engineered cellular nanoparticles for biomedical applications.
Krishnan N; Peng FX; Mohapatra A; Fang RH; Zhang L
Biomaterials; 2023 May; 296():122065. PubMed ID: 36841215
[TBL] [Abstract][Full Text] [Related]
14. Targeting Cancer with Genetically Engineered TCR T Cells.
Smith TW; Nishimura MI
Recent Results Cancer Res; 2020; 214():129-151. PubMed ID: 31473851
[TBL] [Abstract][Full Text] [Related]
15. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379
[TBL] [Abstract][Full Text] [Related]
16. Genetically engineered PD-1 displaying nanovesicles for synergistic checkpoint blockades and chemo-metabolic therapy against non-small cell lung cancer.
Li B; Yang T; Liu J; Yu X; Li X; Qin F; Zheng J; Liang J; Zeng Y; Zhou Z; Liu L; Zhang B; Yao W; Feng Z; Zeng G; Zhou Q; Chen L
Acta Biomater; 2023 Apr; 161():184-200. PubMed ID: 36893957
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic Hybrid Nanovesicles of Liposomes and Tumor-Derived Nanovesicles for Cancer Immunochemotherapy.
Hu M; Zhang J; Kong L; Yu Y; Hu Q; Yang T; Wang Y; Tu K; Qiao Q; Qin X; Zhang Z
ACS Nano; 2021 Feb; 15(2):3123-3138. PubMed ID: 33470095
[TBL] [Abstract][Full Text] [Related]
18. Engineered Microorganisms for Advancing Tumor Therapy.
Jia J; Wang X; Lin X; Zhao Y
Adv Mater; 2024 Jun; 36(24):e2313389. PubMed ID: 38485221
[TBL] [Abstract][Full Text] [Related]
19. Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy.
Chen H; Zhang P; Shi Y; Liu C; Zhou Q; Zeng Y; Cheng H; Dai Q; Gao X; Wang X; Liu G
J Nanobiotechnology; 2022 Feb; 20(1):61. PubMed ID: 35109867
[TBL] [Abstract][Full Text] [Related]
20. Progress of engineered bacteria for tumour therapy.
Xia X; Zhang JW; Zhao B; Zhang M; Chen ZR; Zhang BF; Ji YL; Wang X; Xiong WM; Li JW; Lv QL
Int Immunopharmacol; 2024 May; 132():111935. PubMed ID: 38599096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
